RYVU Therapeutics S.A. — Capital/Financing Update 2024

Jun 17, 2024

Report Content Fulfillment of conditions for the disbursement of the Tranche B offinancing from the European Investment Bank

The Management Board of Ryvu Therapeutics S.A. with its registeredoffice in Krakow ("Company"), with reference to current reports no.14/2022 of August 17, 2022, no. 19/2023 of May 5, 2023, no. 33/2023 ofJune 19, 2023, no. 2/2024 of January 17, 2024, no. 4/2023 of January 30,2024, and no. 12/2024 of March 6, 2024 (subsequently amended by acurrent report 12K/2024 dated March 7, 2024) hereby informs that on June17, 2024, the Company received from the European Investment Bank (_quot;EBI_quot;)confirmation that the Company has fulfilled all conditions for thedisbursement of the second tranche of financing (_quot;Tranche B_quot;) under thefinancing agreement concluded on August 16, 2022.

As a result, the Company expects to receive on June 25, 2024, an amountof EUR 8,000,000.00 (34,864,800.00 PLN converted at the average exchangerate of the National Bank of Poland on June 14, 2024, 1 EUR = 4.3581).The Company is obligated to repay Tranche B by June 25, 2029.

The Managment Board informs that as of June 14, 2024, the value of theCompany's cash and bonds amounted to PLN 224,575,611.00 This value doesnot include the expected receipt of Tranche B on June 25, 2024, in theamount of EUR 8,000,000.00 as described above.

Disclaimer: This English language translation has been prepared solelyfor the convenience of English-speaking readers. Despite all the effortsdevoted to this translation, certain discrepancies, omissions orapproximations may exist. In case of any differences between the Polishand the English versions, the Polish version shall prevail. RyvuTherapeutics S.A., its representatives and employees decline allresponsibility in this regard.